Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

The Lancet Neurology

Volumn 8, Issue 7, 2009, Pages 619-627

  Visser, Pieter Jelle ^a,b   Verhey, Frans ^a   Knol, Dirk L ^c   Scheltens, Philip ^b   Wahlund, Lars Olof ^e   Freund Levi, Yvonne ^e   Tsolaki, Magda ^h   Minthon, Lennart ^f   Wallin, Åsa K ^f   Hampel, Harald ^i,j   Bürger, Katharina ⁱ   Pirttila, Tuula ^k   Soininen, Hilkka ^k   Rikkert, Marcel Olde ^d   Verbeek, Marcel M ^d   Spiru, Luiza ^l   Blennow, Kaj ^g  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e KAROLINSKA INSTITUTE   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j TRINITY COLLEGE DUBLIN   (Ireland)

^k KUOPIO UNIVERSITY HOSPITAL   (Finland)

^l CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 67649628753     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70139-5     Document Type: Article

References (49)

1. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 (2006) 228-234
2. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
3. Buerger K., Ewers M., Pirttila T., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129 (2006) 3035-3041
4. Tapiola T., Alafuzoff I., Herukka S.K., et al. Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66 (2009) 382-389
5. Visser P.J., Verhey F.R.J., Boada M., et al. Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA study. Neuroepidemiology 30 (2008) 254-265
6. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state", a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
7. Morris J. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
9. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
10. Sheikh J., and Yesavage J. Geriatric depression scale (GDS): recent evidence and development of a shorter version. Clinical gerontology: a guide to assessment and intervention (1986), The Haworth Press, New York 165-173
11. Alexopoulos G.S., Abrams R.C., Young R.C., and Shamoian C.A. Cornell scale for depression in dementia. Biol Psychiatry 23 (1988) 271-284
12. Van der Elst W., van Boxtel M.P., van Breukelen G.J., and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 11 (2005) 290-302
13. Welsh K.A., Butters N., Mohs R.C., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 44 (1994) 609-614
14. Van der Elst W., Van Boxtel M.P., Van Breukelen G.J., and Jolles J. Normative data for the animal, profession and letter naming verbal fluency tests for Dutch-speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 12 (2006) 80-89
15. Reitan R. Validity of the trail making test as an indication of organic brain damage. Percept Mot Skills 8 (1958) 271-276
16. Rey A. L'examen psychologie dans les cas d'encephalopathie traumatique. Archives de Psychologie 28 (1941) 286-340
17. Hulstaert F., Blennow K., Ivanoiu A., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
18. Andreasen N., Minthon L., Vanmechelen E., et al. Cerebrospinal fluid tau and A-beta-42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273 (1999) 5-8
19. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., and Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59 (2002) 1729-1734
20. Herukka S.-K., Hallikainen M., Soininen H., and Pirttila T. CSF A(beta)42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64 (2005) 1294-1297
21. Scheltens P., Leys D., Barkhof F., et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55 (1992) 967-972
22. Brandt J., Spencer M., and Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1 (1988) 111-117
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. (1994), American Psychiatric Association, Washington DC
24. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work-group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
25. Neary D., Snowden J.S., Gustafson L., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998) 1546-1554
26. Roman G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 43 (1993) 250-260
27. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
28. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 80 (1993) 27-38
29. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57 (1995) 289-300
30. Andreasen N., Minthon L., Davidsson P., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (2001) 373-379
31. Lindeboom J., Schmand B., Tulner L., Walstra G., and Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 73 (2002) 126-133
32. Chandler M.J., Lacritz L.H., Cicerello A.R., et al. Three-word recall in normal aging. J Clin Exp Neuropsychol 26 (2004) 1128-1133
33. Spreen O., and Strauss E. A compendium of neuropsychological tests. 2nd edn. (1998), Oxford University Press, New York
34. Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol 18 (1935) 643-662
35. Pike K.E., Savage G., Villemagne V.L., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007) 2837-2844
36. Nobili F., Frisoni G.B., Portet F., et al. Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study. J Neurol 255 (2008) 1344-1353
37. Jauhiainen A.M., Kangasmaa T., Rusanen M., et al. Differential hypometabolism patterns according to mild cognitive impairment subtypes. Dement Geriatr Cogn Disord 26 (2008) 490-498
38. Whitwell J.L., Petersen R.C., Negash S., et al. Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol 64 (2007) 1130-1138
39. Lehtovirta M., Laakso M.P., Soininen H., et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 67 (1995) 65-72
40. Galasko D., Chang L., Motter R., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
41. Galton C.J., Patterson K., Xuereb J.H., and Hodges J.R. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123 (2000) 484-498
42. Shaw L.M., Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009) 403-413
43. Li G., Sokal I., Quinn J.F., et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69 (2007) 631-639
44. Stomrud E., Hansson O., Blennow K., Minthon L., and Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24 (2007) 118-124
45. Mintun M.A., Larossa G.N., Sheline Y.I., et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67 (2006) 446-452
46. Wiley C.A., Lopresti B.J., Venneti S., et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66 (2009) 60-67
47. Ewers M., Buerger K., Teipel S.J., et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69 (2007) 2205-2212
48. Bateman R.J., Wen G., Morris J.C., and Holtzman D.M. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68 (2007) 666-669
49. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746